Hervolution Therapeutics ApS (formerly Inprother Aps) has announced a $11.7 million series A financing to support its work developing novel human endogenous retrovirus (HERV)-targeted immunotherapies to address diseases of aging.
Engineered probiotics, mainly bacterial probiotics, are an emerging platform for in situ delivery of therapeutics, including anticancer therapies, to the gut. Writing in Cell Chemical Biology, researchers from Washington University School of Medicine and collaborators present a novel yeast-based therapeutic oral platform to deliver next-generation immune checkpoint inhibitor proteins directly to gastrointestinal tumors.
Biopolar Hongye (Nantong) Pharmaceutical Co., Ltd. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon (CRBN) binding moiety covalently linked to a Bruton’s tyrosine kinase (BTK) binding moiety reported to be useful for the treatment of cancer, inflammatory and autoimmune diseases.
Deciphera Pharmaceuticals LLC has divulged eukaryotic translation initiation factor 2-α kinase 3 (PERK) and/or GCN2 inhibitors reported to be useful for the treatment of cancer and amyloidosis.
Solve Therapeutics Inc. has identified antibody-drug conjugates comprising an UC-961 antibody or a tyrosine-protein kinase transmembrane receptor ROR2 (ROR2)-targeting antibody covalently linked to exatecan through a linker reported to be useful for the treatment of cancer.
Cstone Pharmaceuticals Co. Ltd. has filed a clinical trial application in Australia seeking to initiate a first-in-human study of CS-2009 for solid tumors. The company plans to initiate a multi-regional trial for CS-2009 in Australia early next year, followed by expansion into China and the U.S.
Differentiated thyroid cancers (DTC) and anaplastic thyroid cancers (ATC) often develop primary and acquired resistance to standard treatments. This highlights the need for new therapeutic strategies to treat these thyroid tumors. Previous research observed that the pyrimidine ring of the 2,4-diaminopyrimidine moiety could often form critical hydrogen bonds with kinases, leading to strong inhibitory activity.
Radiopharm Theranostics Ltd. has been granted Belberry Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human phase I therapeutic study of 177Lu-labeled RAD-202 (177Lu-RAD-202) for the treatment of HER2-expressing solid tumors, including breast and gastric cancers.
Beigene Co. Ltd. has presented data on a CDK4 selective inhibitor, BGB-43395, for the potential treatment of this cancer type and which would reduce the neutropenia associated with CDK6 inhibition.
RSS
